News Category
A new study reveals that the bacterial strains in a person's microbiome influence their risk of developing sepsis, meningitis, or pneumonia from air p...
Experts emphasize that asking about clinical trials at the first appointment can open doors to promising new treatments and better quality of life for...
GeoVax's agreement with CEPI to use its Centralised Laboratory Network for the GEO-MVA Phase 3 trial aims to generate independent, standardized data t...
Preclinical research published in Science Advances demonstrates that engineered suppressor tRNAs can restore full-length dystrophin and improve muscle...
Creative Biolabs has expanded its functionalized lipid-based delivery system development capabilities, offering customized targeted and stimuli-respon...
BioCorRx Inc. appointed Richard J. Baum, former Acting Director of the White House Office of National Drug Control Policy, to its Strategic Advisory B...
Regentis Biomaterials reported first half 2026 financial results, highlighted progress in its Phase III GelrinC trial, and announced a 400% production...
Quantum BioPharma's FDA clearance for a Phase 2 trial of Lucid-MS represents a potential paradigm shift in multiple sclerosis treatment by targeting m...
Regentis Biomaterials advances GelrinC, a hydrogel implant designed to regenerate knee cartilage, as an alternative to symptom management, with Europe...
VERAXA Biotech's appointment of Dr. Christoph Erkel as CSO signals a strategic push to advance its BiTAC® T-cell engager and broader oncology pipeline...
Quantum BioPharma's Lucid-MS, a first-in-class PAD2 inhibitor, has received FDA clearance to begin a Phase 2 trial in multiple sclerosis, potentially ...
Quantum BioPharma's FDA clearance to launch a phase 2 trial of Lucid-MS, a first-in-class myelin-repair therapy for multiple sclerosis, represents a h...
Quantum BioPharma receives FDA clearance to launch a phase 2 trial of Lucid-MS, a first-in-class multiple sclerosis drug designed to protect and rebui...
Helus Pharma's CEO will present at the Morgan Stanley Global Healthcare Conference, highlighting the company's advanced clinical programs for depressi...
Onco-Innovations' CMO Dr. Islam Mohamed detailed the company's novel PNKP-targeting drug candidate ONC010 on the BioMedWire podcast, emphasizing its p...
Quantum BioPharma's Lucid-MS, a first-in-class non-covalent PAD2 inhibitor, is moving toward a Phase 2 trial for multiple sclerosis following FDA clea...
A looming crisis in urinary tract infection (UTI) diagnosis is highlighted, emphasizing the need for advanced diagnostic tools to address recurrent in...
Silo Pharma's participation in the IPAC-RS 2026 Nasal Innovation Forum underscores its commitment to advancing SPC-15, a nose-to-brain therapy for PTS...
Quantum BioPharma's FDA clearance for Lucid-MS Phase 2 trial marks a pivotal milestone in developing a first-in-class therapy that could repair myelin...
Quantum BioPharma's Lucid-MS, a first-in-class myelin-protective multiple sclerosis drug candidate, has received FDA clearance to begin a Phase 2 tria...
GeoVax supports the new global mpox vaccine stockpile and emphasizes its GEO-MVA candidate's readiness to bolster diversified vaccine supply.
VERAXA Biotech's appointment of seasoned financial executive Raju Willener as CFO underscores its commitment to advancing its BiTAC platform and oncol...
Scinai Immunotherapeutics strategically shifts its R&D focus to its NanoAb platform and CDMO business after terminating its PC111 license with PinCell...
Onco-Innovations advances its oncology pipeline by building manufacturing capabilities, IND-enabling activities, and capital foundation ahead of plann...
A study from Washington University School of Medicine highlights the growing role of laser interstitial thermal therapy (LITT) in brain cancer treatme...
Quantum BioPharma's FDA clearance for Lucid-MS, a first-in-class remyelinating agent, marks a pivotal step toward a treatment that could potentially r...
Ocumetics Technology Corp. has initiated patient recruitment for the Group Two phase of its human clinical study, aiming to evaluate the safety and vi...
Quantum BioPharma's FDA clearance for a Phase 2 trial of Lucid-MS, a first-in-class myelin repair candidate, could challenge the current treatment par...
NanoViricides has registered its Phase II Ebola trial for NV-387 Oral Gummies in the Pan African Clinical Trials Registry, marking a critical step in ...
Quantum BioPharma's FDA clearance to advance Lucid-MS into Phase 2 trials for multiple sclerosis marks a pivotal step toward a targeted therapy that c...
Quantum BioPharma received FDA clearance to begin a Phase 2 trial of Lucid-MS in multiple sclerosis, marking a key step for a first-in-class candidate...
Quantum BioPharma's FDA clearance for Lucid-MS Phase 2 trial could redefine multiple sclerosis therapy by targeting demyelination, offering a novel ap...
Tonix Pharmaceuticals' promotion of Thomas Englese to Chief Commercial Officer underscores the company's strategic focus on commercializing its fibrom...
A new study reveals that the timing of brain metastasis development in colorectal cancer patients significantly impacts survival, highlighting the nee...
Onco-Innovations' ONC010 progresses through key preclinical milestones, including high-purity API production and a novel catalyst, positioning it for ...
OS Therapies' participation at the Moody Capital Solutions conference underscores its strategic positioning ahead of pivotal regulatory decisions and ...
A Swiss preclinical study reveals that administering immunotherapy prior to surgical removal of glioblastoma tumors significantly improves treatment o...
The FDA's failure to aggressively enforce laws against the illegal sale of the investigational drug retatrutide has created a dangerous digital black ...
New research from Mass General Brigham reveals that unintended radiation exposure to the thymus during lung cancer treatment is linked to worse clinic...
Tonix Pharmaceuticals' participation in the Cantor conference underscores its strategic focus on advancing treatments for fibromyalgia, CNS disorders,...
NurExone Biologic's participation at a New York conference underscores its strategic pivot to U.S. manufacturing and commercialization, highlighting t...
CNS Pharmaceuticals' Chief Business Officer Dylan Wenke details the company's strategic approach to identify and acquire best-in-class oncology and ne...
Dr. Salman Fazal's 2026 Castle Connolly Top Doctor honor highlights his pioneering work in stem cell transplantation and cellular therapies, underscor...
Quantum BioPharma Ltd. has been initiated with a 'Buy' rating and an $8.00 price target by Rodman & Renshaw, highlighting the potential of its lead dr...
NanoViricides is progressing its measles treatment NV-387 toward Phase II clinical trials, leveraging FDA designations and promising preclinical data,...
TransCode Therapeutics announced preclinical results showing its lead candidate TTX-MC138 significantly improves survival in a breast cancer bone meta...
Oragenics reports progress in its Phase IIa trial for ONP-002, receives FDA feedback, and addresses NYSE American listing compliance, underscoring its...
A nurse's battle with metastatic triple-negative breast cancer underscores the significance of newer ADC therapies and the need for patients to ask in...
